Trade

with

CytRx Corp
(NASDAQ: CYTR)
AdChoices
2.67
-0.09
-3.26%
After Hours :
2.67
0.00
0.00%

Open

2.77

Previous Close

2.76

Volume (Avg)

535.72k (830.10k)

Day's Range

2.65-2.79

52Wk Range

2.00-8.35

Market Cap.

153.87M

Dividend Rate ( Yield )

-

Beta

1.86

Shares Outstanding

55.75M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 300.00k

    • Net Income

    • -47.49M

    • Market Cap.

    • 153.87M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -48,253.14

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.86

    • Forward P/E

    • -3.33

    • Price/Sales

    • 1,250.00

    • Price/Book Value

    • 1.85

    • Price/Cash flow

    • -4.01

      • EBITDA

      • -27.47M

      • Return on Capital %

      • -71.54

      • Return on Equity %

      • -93.09

      • Return on Assets %

      • -71.54

      • Book Value/Share

      • 1.49

      • Shares Outstanding

      • 55.75M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 11.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.80

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -45.55

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -48,251.54

            • 39.38

            • Net Profit Margin

            • -48,253.14

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -7,833.70

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -7,840.80

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 4.67

              • 2.92

              • Quick Ratio

              • 4.63

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.27

              • 2.21

              • Book Value/Share

              • 1.49

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.53

                • 196.08

                • P/E Ratio 5-Year High

                • -10.00

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.46

                • 124.82

                • Price/Sales Ratio

                • 1,250.00

                • 9.12

                • Price/Book Value

                • 1.85

                • 8.26

                • Price/Cash Flow Ratio

                • -4.01

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -93.09

                    (-74.30)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -71.54

                    (-43.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -93.09

                    (-74.30)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.00

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -27.59M
                  Operating Margin
                  -9,198.15
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -4.01
                  Ownership

                  Institutional Ownership

                  39.36%

                  Top 10 Institutions

                  33.91%

                  Mutual Fund Ownership

                  15.89%

                  Float

                  98.39%

                  5% / Insider Ownership

                  9.10%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • JPM Global Healthcare

                  •  

                    1,348,039

                  • -4.51

                  • 2.42

                  • iShares Russell 2000 (AU)

                  •  

                    858,928

                  • -1.02

                  • 1.66

                  • Vanguard Total Stock Mkt Idx

                  •  

                    766,943

                  • 0.00

                  • 1.38

                  • Franklin Biotechnology Discovery Fund

                  •  

                    589,000

                  • 0.00

                  • 1.06

                  • Vanguard Extended Market Index Fund

                  •  

                    544,515

                  • 0.00

                  • 0.98

                  • Allianz Biotechnologie

                  •  

                    327,210

                  • 0.00

                  • 0.60

                  • iShares Russell 2000 Value

                  •  

                    269,433

                  • 0.35

                  • 0.52

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Qvt Financial LP

                  •  

                    4,619,900

                  • -10.55%

                  • 8.26

                  • Franklin Advisers, Inc.

                  •  

                    1,915,900

                  • 0.00%

                  • 3.43

                  • Vanguard Group, Inc.

                  •  

                    1,880,813

                  • +49.76%

                  • 3.36

                  • BlackRock Fund Advisors

                  •  

                    1,721,622

                  • +55.65%

                  • 3.08

                  • J P Morgan Asset Management (UK) Ltd

                  •  

                    1,659,080

                  • -11.42%

                  • 2.97

                  • Baker Bros Advisors LLC

                  •  

                    1,350,000

                  • 0.00%

                  • 2.41

                  • Kennedy Capital Management Inc

                  •  

                    553,879

                  • +9.32%

                  • 0.99

                  • State Street Corp

                  •  

                    542,765

                  • +1,561.10%

                  • 0.97

                  • Sphera Funds Management Ltd.

                  •  

                    400,000

                  • -1.23%

                  • 0.72

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various ...morestages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally...more bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company’s plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.lessless

                  Key People

                  Steven A. Kriegsman

                  CEO/President/Director

                  Marvin R. Selter

                  Director/Vice Chairman of the Board

                  Dr. Max E. Link,PhD

                  Chairman of the Board/Director

                  John Y. Caloz

                  CFO/Chief Accounting Officer

                  Dr. Daniel J. Levitt,M.D.,PhD

                  Chief Medical Officer/Executive VP

                  • CytRx Corp

                  • 11726 San Vicente Boulevard

                  • Los Angeles, CA 90049

                  • USA.Map

                  • Phone: +1 310 826-5648

                  • Fax: +1 310 826-6139

                  • cytrx.com

                  Incorporated

                  1985

                  Employees

                  17

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: